Company facts
- Headquarters
- La Jolla, California
- Most recent report
- 8-K, filed Aug 13, 2026
- Incorporated
- Delaware
- Filings on record
- 137 filings
- On EDGAR
- CIK 2007919
- Fiscal year ends
- December
- Filer status
- Emerging growth company
Financials 8 of 9
News 8 of 25
Prospectuses and Registrations 8 of 15
- POS AM Post-effective amendment to a registration Jun 2, 2025
- 424B3 Prospectus supplement for an offering May 28, 2025
- 424B3 Prospectus supplement for an offering May 14, 2025
- POS AM Post-effective amendment to a registration Apr 17, 2025
- 424B3 Prospectus supplement for an offering Apr 1, 2025
- 424B3 Prospectus supplement for an offering Mar 17, 2025
- 424B3 Prospectus supplement for an offering Jan 21, 2025
- 424B3 Prospectus supplement for an offering Jan 13, 2025
Proxies 4
Ownership 8 of 64
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 3, 2026
- 4 Insider reported a trade Jun 4, 2026
- 4 Insider reported a trade Jun 4, 2026
- 4 Insider reported a trade Jun 4, 2026
- 4 Insider reported a trade Jun 4, 2026
Other 8 of 20
- ARS Annual report sent to shareholders Apr 23, 2026
- EFFECT Notice that a registration became effective Jun 4, 2025
- EFFECT Notice that a registration became effective Apr 18, 2025
- ARS Annual report sent to shareholders Apr 17, 2025
- POS EX Mar 17, 2025
- EFFECT Notice that a registration became effective Jun 18, 2024
- CORRESP Reply to SEC staff Jun 14, 2024
- UPLOAD Comment letter from SEC staff Jun 14, 2024
Everything here comes from Inhibrx Biosciences, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.